Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| VEGF Inhibitors Disappoint in Adjuvant Renal Cell Carcinoma - Medscape |
 |
 |
|
Medscape Neither sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals) nor sunitinib (Sutent, Pfizer Inc), when given in the adjuvant setting, prolong disease-free survival (DFS) in patients with completely resected, locally advanced renal cell carcinoma (RCC ... No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell ... Oncology Nurse Advisor Sorafenib, sunitinib provide no benefit to patients with locally advanced |
